Literature DB >> 23071129

Health-related quality of life after renal denervation in patients with treatment-resistant hypertension.

Gavin W Lambert1, Dagmara Hering, Murray D Esler, Petra Marusic, Elisabeth A Lambert, Stephanie K Tanamas, Jonathan Shaw, Henry Krum, John B Dixon, David A Barton, Markus P Schlaich.   

Abstract

Recent studies have demonstrated the effectiveness of radiofrequency ablation of the renal sympathetic nerves in reducing blood pressure (BP) in patients with resistant hypertension. The effect of renal denervation on health-related quality of life (QoL) has not been evaluated. Using the Medical Outcomes Study 36-Item Short-Form Health Survey and Beck Depression Inventory-II, we examined QoL before and 3 months after renal denervation in patients with uncontrolled BP. For baseline comparisons, matched data were extracted from the Australian Diabetes, Obesity, and Lifestyle database. Before renal denervation, patients with resistant hypertension (n = 62) scored significantly worse in 5 of the eight 36-Item Short-Form Health Survey domains and the Mental Component Summary score. Three months after denervation (n = 40), clinic BP was reduced (change in systolic and diastolic BP, -16 ± 4 and -6 ± 2 mm Hg, respectively; P<0.01). The Mental Component Summary score improved (47.6 ± 1.1 versus 52 ± 1; P = 0.001) as a result of increases in the vitality, social function, role emotion, and mental health domains. Beck Depression Inventory scores were also improved, particularly with regard to symptoms of sadness (P = 0.01), tiredness (P<0.001), and libido (P<0.01). The magnitude of BP reduction or BP level achieved at 3 months bore no association to the change in QoL. Renal denervation was without a detrimental effect on any elements of the 36-Item Short-Form Health Survey. These results indicate that patients with severe hypertension resistant to therapy present with a marked reduction in subjective QoL. In this pre- and post-hypothesis generating study, several aspects of QoL were improved after renal denervation; however, this was not directly associated with the magnitude of BP reduction.

Entities:  

Mesh:

Year:  2012        PMID: 23071129     DOI: 10.1161/HYPERTENSIONAHA.112.200865

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  22 in total

Review 1.  Role of the Sympathetic Nervous System in Stress-Mediated Cardiovascular Disease.

Authors:  Dagmara Hering; Kamila Lachowska; Markus Schlaich
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

2.  Activation of afferent renal nerves modulates RVLM-projecting PVN neurons.

Authors:  Bo Xu; Hong Zheng; Xuefei Liu; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-01-30       Impact factor: 4.733

Review 3.  Device-Based Therapy for Drug-Resistant Hypertension: An Update.

Authors:  Ping Li; Mark Nader; Kousalya Arunagiri; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

Review 4.  The Role of Central Nervous System Mechanisms in Resistant Hypertension.

Authors:  Dagmara Hering; Markus Schlaich
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

Review 5.  Quality of Life in Treatment-Resistant Hypertension.

Authors:  Nicholas W Carris; Steven M Smith
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

6.  Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives.

Authors:  N W Carris; V Ghushchyan; A M Libby; S M Smith
Journal:  J Hum Hypertens       Date:  2015-06-18       Impact factor: 3.012

Review 7.  Integration of renal sensory afferents at the level of the paraventricular nucleus dictating sympathetic outflow.

Authors:  Hong Zheng; Kaushik P Patel
Journal:  Auton Neurosci       Date:  2016-08-06       Impact factor: 3.145

8.  Catheter-based Renal Sympathetic Denervation - Long-term Symplicity™ Renal Denervation Clinical Evidence, New Data and Future Perspectives.

Authors:  Katrina Mountfort; Felix Mahfoud; Roland Schmieder; Justin Davies; David E Kandzari; Joachim Weil; Robert Whitbourn
Journal:  Interv Cardiol       Date:  2013-08

Review 9.  Obesity-associated hypertension: recent progress in deciphering the pathogenesis.

Authors:  Kamal Rahmouni
Journal:  Hypertension       Date:  2014-08       Impact factor: 10.190

Review 10.  The role of renal denervation for the treatment of resistant hypertension.

Authors:  A J A McLellan; P M Kistler; A S Walton; M P Schlaich
Journal:  J Hum Hypertens       Date:  2013-10-03       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.